Evidence map›Paper›PMID 40868613›Full record

ReviewHealthcare (Basel, Switzerland)2025

Building Lay Society Knowledge and Education for Health Technology Assessment and Policy Engagement: Case of CFTR Modulator Access in Brazil.

Verônica Stasiak Bednarczuk de Oliveira, Marise Basso Amaral, Mariana Camargo, Miquéias Lopes-Pacheco

Abstract readReview
In one paragraph

Review in Healthcare (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Verônica Stasiak Bednarczuk de OliveiraUnited for Life Institute-Cystic Fibrosis, Rare and Respiratory Diseases, Curitiba 80420-130, PR, Brazil.ORCID 0000-0002-9528-9374
Marise Basso AmaralUnited for Life Institute-Cystic Fibrosis, Rare and Respiratory Diseases, Curitiba 80420-130, PR, Brazil.ORCID 0000-0002-6259-7194
Mariana CamargoDepartment of Surgery, Division of Urology, São Paulo Federal University, São Paulo 04021-001, SP, Brazil.ORCID 0000-0003-2861-8550
Miquéias Lopes-PachecoDepartment of Pediatrics, Center for Cystic Fibrosis and Airway Disease Research, Emory University School of Medicine, Atlanta, GA 30322, USA.ORCID 0000-0002-7444-9359

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The health technology assessment (HTA) is a multidisciplinary process utilized to determine the clinical, economic, social, and ethical value of new health technologies before they are incorporated into healthcare systems. In the case of rare diseases, such as Cystic Fibrosis (CF), challenges arise due to limited evidence and high treatment costs. Indeed, although CF transmembrane conductance regulator (CFTR) modulators are breakthrough therapies for CF, their incorporation into public health systems has been complex with considerable challenges, especially in low- and middle-income countries. This article presents a descriptive and exploratory case study of the regulatory and policy journey for CFTR modulators to be approved in Brazil. Based on a narrative review and document analysis, we highlight the importance of building lay society knowledge to shape policy decisions and promote equitable access to innovative therapies. In parallel, we critically reflect on the HTA process and highlight efforts in the training, education, and coordination required to enable meaningful public engagement and landmark achievements.

Indexed as

cystic fibrosishealthcare disparitieshealth policypatient advocacypersonalized careprecision medicinepublic health educationrare diseasestakeholder engagement

Identifiers

PMID40868613
PMCPMC12385758

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.